SANOFI-AVENTIS (EPA:SAN) Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Transparency directive : regulatory news
07/12/2023 07:35